Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 6,21 MB, PDF-dokument

  • Florian Kronenberg
  • Samia Mora
  • Erik S.G. Stroes
  • Brian A. Ference
  • Benoit J. Arsenault
  • Lars Berglund
  • Marc R. Dweck
  • Marlys L. Koschinsky
  • Gilles Lambert
  • François Mach
  • Catherine J. McNeal
  • Patrick M. Moriarty
  • Pradeep Natarajan
  • Klaus G. Parhofer
  • Salim S. Virani
  • Arnold von Eckardstein
  • Gerald F. Watts
  • Jane K. Stock
  • Kausik K. Ray
  • Lale S. Tokgözoğlu
  • Alberico L. Catapano
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. One of the novelties of this statement is a new risk calculator showing how Lp(a) influences lifetime risk for ASCVD and that global risk may be underestimated substantially in individuals with high or very high Lp(a) concentration. The statement also provides practical advice on how knowledge about Lp(a) concentration can be used to modulate risk factor management, given that specific and highly effective mRNA-targeted Lp(a)-lowering therapies are still in clinical development. This advice counters the attitude: "Why should I measure Lp(a) if I can't lower it?". Subsequent to publication, questions have arisen relating to how the recommendations of this statement impact everyday clinical practice and ASCVD management. This review addresses 30 of the most frequently asked questions about Lp(a) epidemiology, its contribution to cardiovascular risk, Lp(a) measurement, risk factor management and existing therapeutic options.
Sider (fra-til)107-120
Antal sider14
StatusUdgivet - 2023

Bibliografisk note

Publisher Copyright:
© 2023 The Authors

ID: 360066193